Updates on the Pathophysiology and Management of Acne Rosacea

References

• . Wilkin J, Dahl M, Detmar M, .; National Rosacea Society Expert Committee. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2004;50(6):907–912
   PubMed Web of Science ®Google Scholar
• . National Rosacea Society. What is rosacea? http://www.rosacea.org. Accessed January 20, 2009
   Google Scholar
• . Del Rosso JQ. Update on rosacea pathogenesis and correlation with medical therapeutic agents. Cutis. 2006;78(2):97–100
   PubMed Web of Science ®Google Scholar
• . Gupta AK, Gover MD. Azelaic acid (15% gel) in the treatment of acne rosacea. Int J Dermatol. 2007;46(5):533–538
   PubMed Web of Science ®Google Scholar
• . Breathnach AS. Azelaic acid: potential as a general antitumoural agent. Med Hypothesis. 1999;52(3):221–226
   PubMed Web of Science ®Google Scholar
• . van Zuuren EJ, Gupta AK, Gover MD, Graber M, Hollis S. Systematic review of rosacea treatments. J Am Acad Dermatol. 2007;56(1):107–115
   PubMed Web of Science ®Google Scholar
• . Liu RH, Smith MK, Basta SA, Farmer ER. Azelaic acid in the treatment of papulopustular rosacea: a systematic review of randomized controlled trials. Arch Dermatol. 2006;142(8):1047–1052
   PubMedGoogle Scholar
• . Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol. 2003;48(6):836–845
   PubMed Web of Science ®Google Scholar
• . Elewski BE, Fleischer AB Jr, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol. 2003;139(11):1444–1450
   PubMedGoogle Scholar
• . Bikowski JB, Goldman MP. Rosacea: where are we now? J Drugs Dermatol. 2004;3(3):251–261
   PubMedGoogle Scholar
• . Maddin S. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol. 1999;40(6 pt 1):961–965
   PubMed Web of Science ®Google Scholar
• . Thiboutot DM, Fleischer AB Jr, Del Rosso JQ, Graupe K. Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. J Drugs Dermatol. 2008;7(6):541–546
   PubMed Web of Science ®Google Scholar
• . McClellan KJ, Noble S. Topical metronidazole. A review of its use in rosacea. Am J Clin Dermatol. 2000;1(3):191–199
   PubMedGoogle Scholar
• . Nally JB, Berson DS. Topical therapies for rosacea. J Drugs Dermatol. 2006;5(1):23–26
   PubMedGoogle Scholar
• . Jorizzo JL, Lebwohl M, Tobey RE. The efficacy of metronidazole 1% cream once daily compared with metronidazole 1% cream twice daily and their vehicles in rosacea: a double-blind clinical trial. J Am Acad Dermatol. 1998;39(3):502–504
   PubMed Web of Science ®Google Scholar
• . van Zuuren EJ, Graber MA, Hollis S, Chaudhry M, Gupta AK, Gover M. Interventions for rosacea. Cochrane Database Syst Rev. 2005;(3):CD003262
   Google Scholar
• . Tan JK, Girard C, Krol A, . Randomized placebo-controlled trial of metronidazole 1% cream with sunscreen SPF 15 in treatment of rosacea. J Cutan Med Surg. 2002;6(6):529–534
   PubMed Web of Science ®Google Scholar
• . Nielsen PG. A double-blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. Br J Dermatol. 1983;109(1):63–65
   PubMed Web of Science ®Google Scholar
• . Veien NK, Christiansen JV, Hjorth N, Schmidt H. Topical metronidazole in the treatment of rosacea. Cutis. 1986;38(3):209–210
   PubMed Web of Science ®Google Scholar
• . Sauder DN, Miller R, Gratton D, . The treatment of rosacea: the safety and efficacy of sodium sulfacetamide 10% and sulfur 5% lotion (Novacet) is demonstrated in a double-blind study. J Dermatolog Treat. 1997;8(2):79–85
   Web of Science ®Google Scholar
• . Lebwohl M, Medansky RS, Russo CL, . The comparative efficacy of sodium sulfacetamide 10%/sulfur 5% (Sulfacet-R®) lotion and metronidazole 0.75% (Metrogel®) in the treatment of rosacea. J Geriatr Dermatol. 1995;3(5):183–185
   Google Scholar
• . Trumbore MW, Goldstein JA, Gurge RM. Treatment of papulopustular rosacea with sodium sulfacetamide 10%/sulfur 5% emollient foam. J Drugs Dermatol. 2009;8(3):299–304
   PubMedGoogle Scholar
• . Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol. 2004;51(4):499–512
   PubMed Web of Science ®Google Scholar
• . Del Rosso JQ. A status report on the medical management of rosacea: focus on topical therapies. Cutis. 2002;70(5):271–275
   PubMed Web of Science ®Google Scholar
• . Berman B, Zell D. Subantimicrobial dose doxycycline: a unique treatment for rosacea. Cutis. 2005;75( suppl 4):19–24
   PubMed Web of Science ®Google Scholar
• . Theobald K, Bradshaw M, Leyden J. Anti-inflammatory dose doxycycline (40 mg controlled-release) confers maximum anti-inflammatory efficacy in rosacea. Skinmed. 2007;6(5):221–226
   PubMedGoogle Scholar
• . Thiboutot DM, Fleischer AB, Del Rosso JQ, Rich P. A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy. J Drugs Dermatol. 2009;8(7):639–648
   PubMed Web of Science ®Google Scholar
• . Pye RJ, Burton JL. Treatment of rosacea by metronidazole. Lancet. 1976;1(7971):1211–1212
   PubMed Web of Science ®Google Scholar
• . Saihan EM, Burton JL. A double-blind trial of metronidazole versus oxytetracycline therapy for rosacea. Br J Dermatol. 1980;102(4):443–445
   PubMedGoogle Scholar
• . Nielsen PG. A double-blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. Br J Dermatol. 1983;109(1):63–65
   PubMed Web of Science ®Google Scholar
• . Baldwin HE. Systemic therapy for rosacea. Skin Therapy Lett. 2007;12(2):1–5
   PubMedGoogle Scholar
• . Torresani C. Clarithromycin: a new perspective in rosacea treatment. Int J Dermatol. 1998;37(5):347–349
   PubMed Web of Science ®Google Scholar
• . Torresani C, Pavesi A, Manara GC. Clarithromycin versus doxycycline in the treatment of rosacea. Int J Dermatol. 1997;36(12):942–946
   PubMed Web of Science ®Google Scholar
• . Korting H, Schöllmann C. Current topical and systemic approaches to treatment of rosacea. J Eur Acad Dermatol Venereol. 2009; 23(8):876–882
   PubMed Web of Science ®Google Scholar
• . Fowler JF Jr. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J Drugs Dermatol. 2007;6(6):641–645
   PubMedGoogle Scholar
• . Butterwick KJ, Butterwick LS, Han A. Laser and light therapies for acne and rosacea. J Drugs Dermatol. 2006;5(1):35–39
   PubMedGoogle Scholar
• . Jørgensen GF, Hedelund L, Haedersdal M. Long-pulsed dye laser versus intense pulsed light for photodamaged skin: a randomized split-face trial with blinded response evaluation. Lasers Surg Med. 2008;40(5):293–299
   PubMed Web of Science ®Google Scholar
• . Bernstein EF, Kligman A. Rosacea treatment using the new-generation, high-energy, 595 nm, long pulse-duration pulsed-dye laser. Lasers Surg Med. 2008;40(4):233–239
   PubMed Web of Science ®Google Scholar
• . Tan SR, Tope WD. Pulsed dye laser treatment of rosacea improves erythema, symptomatology, and quality of life. J Am Acad Dermatol. 2004;51(4):592–299
   PubMed Web of Science ®Google Scholar
• . Larson AA, Goldman MP. Recalcitrant rosacea successfully treated with multiplexed pulsed dye laser. J Drugs Dermatol. 2007;6(8):843–845
   PubMedGoogle Scholar
• . Papageorgiou P, Clayton W, Norwood S, Chopra S, Rustin M. Treatment of rosacea with intense pulsed light: significant improvement and long-lasting results. Br J Dermatol. 2008;159(3):628–632
   PubMed Web of Science ®Google Scholar
• . Neuhaus IM, Zane LT, Tope WD. Comparative efficacy of nonpurpuragenic pulsed dye laser and intense pulsed light for erythematotelangiectatic rosacea. Dermatol Surg. 2009;35(6):920–928
   PubMed Web of Science ®Google Scholar
• . Nybaek H, Jemec GB. Photodynamic therapy in the treatment of rosacea. Dermatology. 2005;211(2):135–138
   PubMed Web of Science ®Google Scholar
• . Bryld LE, Jemec GB. Photodynamic therapy in a series of rosacea patients J Eur Acad Dermatol Venereol. 2007;21(9):1199–1202
   PubMed Web of Science ®Google Scholar
• . Chen CJ, Kono H, Golenbock D, Reed G, Akira S, Rock KL. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med. 2007;13(7):851–856
   PubMed Web of Science ®Google Scholar
• . Taylor KR, Yamasaki K, Radek KA, . Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on Toll-like receptor 4, CD44, and MD-2. J Biol Chem. 2007;282(25):18265–18275
   PubMed Web of Science ®Google Scholar
• . Shibata M, Katsuyama M, Onodera T, Ehama R, Hosoi J, Tagami H. Glucocorticoids enhance Toll-like receptor 2 expression in human keratinocytes stimulated with Propionibacterium acnes or proinflammatory cytokines. J Invest Dermatol. 2009;129(2):375–382
   PubMed Web of Science ®Google Scholar
• . Yamasaki K, Di Nardo A, Bardan A, . Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007;13(8):975–980
   PubMed Web of Science ®Google Scholar
• . Schauber J, Dorschner RA, Coda AB, . Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J Clin Invest. 2007;117(3):803–811
   PubMed Web of Science ®Google Scholar
• . De Yang, Chen Q, Schmidt AP, . LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1(FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes and, T-cells. J Exp Med. 2000;192(7):1069–1074
   PubMed Web of Science ®Google Scholar
• . Koczulla R, von Degenfeld G, Kupatt C, . An angiogenic role for the human peptide antibiotic LL-37/hCAP–18. J Clin Invest. 2003;111(11):1665–1672
   PubMed Web of Science ®Google Scholar
• . Gallo RL, Ono M, Povsic T, . Syndecans, cell surface heparan sulfate proteoglycans, are induced by a proline-rich antimicrobial peptide from wounds. Proc Natl Acad Sci U S A. 1994;91(23):11035–11039
   PubMed Web of Science ®Google Scholar
• . Buechner SA. Rosacea: an update. Dermatology. 2005;210(2):100–108
   PubMed Web of Science ®Google Scholar
• . Shanler SD, Ondo AL. Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline. Arch Dermatol. 2007;143(11):1369–1371
   PubMedGoogle Scholar
• . Gomaa AH, Yaar M, Eyada MM, Bhawan J. Lymphangiogenesis and angiogenesis in non-phymatous rosacea. J Cutan Pathol. 2007;34(10):748–753
   PubMed Web of Science ®Google Scholar
• . Brauchle M, Funk JO, Kind P, Werner S. Ultraviolet B and H2O2 are potent inducers of vascular endothelial growth factor expression in cultured keratinocytes. J Biol Chem. 1996;271(36):21793–21797
   PubMed Web of Science ®Google Scholar
• . Koczulla R, von Degenfeld G, Kupatt C, . An angiogenic role for the human peptide antibiotic LL-37/hCAP–18. J Clin Invest. 2003;111(11):1665–1672
   PubMed Web of Science ®Google Scholar
• . Tokumaru S, Sayama K, Shirakata Y, . Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL–37. J Immunol. 2005;175(7):4662–4668
   PubMed Web of Science ®Google Scholar
• . Detmar M, Brown LF, Claffey KP, Yeo KT, . Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med. 1994;180(3):1141–1146
   PubMed Web of Science ®Google Scholar
• . Bakar O, Demirçay Z, Yuksel M, Haklar G, Sanisoglu Y. The effect of azithromycin on reactive oxygen species in rosacea. Clin Exp Dermatol. 2007;32(2):197–200
   PubMed Web of Science ®Google Scholar
• . Jain A, Sangal L, Basal E, Kaushal GP, Agarwal SK. Anti-inflammatory effects of erythromycin and tetracycline on Propionibacterium acnes induced production of chemotactic factors and reactive oxygen species by human neutrophils. Dermatol Online J. 2002;8(2):2
   PubMedGoogle Scholar
• . Young CN, Koepke JI, Terlecky LJ, Borkin MS, Boyd Savoy L, Terlecky SR. Reactive oxygen species in tumor necrosis factor-alpha-activated primary human keratinocytes: implications for psoriasis and inflammatory skin disease. J Invest Dermatol. 2008;128(11):2606–2614
   PubMed Web of Science ®Google Scholar
• . Peus D, Vasa RA, Beyerle A, Meves A, Krautmacher C, Pittelkow MR. UVB activates ERK1/2 and p38 signaling pathways via reactive oxygen species in cultured keratinocytes. J Invest Dermatol. 1999;112(5):751–756
   PubMed Web of Science ®Google Scholar
• . Peus D, Vasa RA, Meves A, . H2O2 is an important mediator of UVB-induced EGF-receptor phosphorylation in cultured keratinocytes. J Invest Dermatol. 1998;110(6):966–971
   PubMed Web of Science ®Google Scholar
• . Miyachi Y, Yoshioka A, Imamura S, Niwa Y. Effect of antibiotics on the generation of reactive oxygen species. J Invest Dermatol. 1986;86(4):449–453
   PubMed Web of Science ®Google Scholar
• . Akamatsu H, Komura J, Asada Y, Miyachi Y, Niwa Y. Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases. Arch Dermatol Res. 1991;283(3):162–166
   PubMed Web of Science ®Google Scholar
• . Akamatsu H, Oguchi M, Nishijima S, . The inhibition of free radical generation by human neutrophils through the synergistic effects of metronidazole with palmitoleic acid: a possible mechanism of action of metronidazole in rosacea and acne. Arch Dermatol Res. 1990;282(7): 449–454
   PubMed Web of Science ®Google Scholar
• . Bielenberg DR, Bucana CD, Sanchez R, Donawho CK, Kripke ML, Fidler IJ. Molecular regulation of UVB-induced cutaneous angiogenesis. J Invest Dermatol. 1998;111(5):864–872
   PubMed Web of Science ®Google Scholar
• . Longuet-Perret I, Schmitt D, Viac J. Tumour necrosis factor-alpha is involved in the contrasting effects of ultraviolet B and ultraviolet A1 radiation on the release by normal human keratinocytes of vascular permeability factor. Br J Dermatol. 1998;138(2):221–224
   PubMed Web of Science ®Google Scholar
• . Naru E, Suzuki T, Moriyama M, . Functional changes induced by chronic UVA irradiation to cultured human dermal fibroblasts. Br J Dermatol. 2005;153( suppl 2):6–12
   PubMed Web of Science ®Google Scholar
• . Wlaschek M, Briviba K, Stricklin GP, Sies H, Scharffetter-Kochanek K. Singlet oxygen may mediate the ultraviolet A-induced synthesis of interstitial collagenase. J Invest Dermatol. 1995;104(2):194–198
   PubMed Web of Science ®Google Scholar
• . Caubet C, Jonca N, Brattsand M, . Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J Invest Dermatol. 2004;122(5):1235–1244
   PubMed Web of Science ®Google Scholar
• . Descargues P, Deraison C, Prost C, . Corneodesmosomal cadherins are preferential targets of stratum corneum trypsin-and chymotrypsin-like hyperactivity in Netherton syndrome. J Invest Dermatol. 2006;126(7):1622–1632
   PubMed Web of Science ®Google Scholar
• . Michael IP, Sotiropoulou G, Pampalakis G, . Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. J Biol Chem. 2005;280(15):14628–14635
   PubMed Web of Science ®Google Scholar
• . Kawaguchi Y, Tanaka H, Okada T, . The effects of ultraviolet A and reactive oxygen species on the mRNA expression of 72-kDa type IV collagenase and its tissue inhibitor in cultured human dermal fibroblasts. Arch Dermatol Res. 1996;288(1):39–44
   PubMed Web of Science ®Google Scholar
• . Lee Y, Kim H, Kim S, . Myeloid differentiation factor 88 regulates basal and UV-induced expressions of IL–6 and MMP-1 in human epidermal keratinocytes. J Invest Dermatol. 2009;129(2):460–467
   PubMed Web of Science ®Google Scholar
• . Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54(2):258–265
   PubMed Web of Science ®Google Scholar
• . Sorsa T, Lindy O, Konttinen YT, Suomalainen K, . Doxycycline in the protection of serum alpha–1-antitrypsin from human neutrophil collagenase and gelatinase. Antimicrob Agents Chemother. 1993;37(3):592–594
   PubMed Web of Science ®Google Scholar
• . Lacey N, Delaney S, Kavanagh K, Powell FC. Mite-related bacterial antigens stimulate inflammatory cells in rosacea. Br J Dermatol. 2007;157(3):474–481
   PubMed Web of Science ®Google Scholar
• . Erbaǧci Z, Ozgöztşi O. The significance of Demodex folliculorum density in rosacea. Int J Dermatol. 1998;37(6):421–425
   PubMed Web of Science ®Google Scholar
• . Costa CP, Kirschning CJ, Busch D. Role of chlamydial heat shock protein 60 in the stimulation of innate immune cells by Chlamydia pneumoniae. Eur J Immunol. 2002;32(9):2460–2470
   PubMed Web of Science ®Google Scholar
• . Gobert AP, Bambou JC, Werts C, . Helicobacter pylori heat shock protein 60 mediates interleukin-6 production by macrophages via a toll-like receptor (TLR)-2-, TLR-4-, and myeloid differentiation factor 88-independent mechanism J Biol Chem. 2004;279(1):245–250
   PubMed Web of Science ®Google Scholar
• . Gürer MA, Erel A, Erbaǧ D, Cašlar K, Atahan C. The seroprevalence of Helicobacter pylori and nitric oxide in acne rosacea. Int J Dermatol. 2002;41(11):768–770
   PubMed Web of Science ®Google Scholar
• . Baz K, Cimen MY, Kokturk A, . Plasma reactive oxygen species activity and antioxidant potential levels in rosacea patients: correlation with seropositivity to Helicobacter pylori. Int J Dermatol. 2004;43(7):494–497
   PubMed Web of Science ®Google Scholar
• . Kawahara T, Kuwano Y, Teshima-Kondo S, . Toll-like receptor 4 regulates gastric pit cell responses to Helicobacter pylori infection. J Med Invest. 2001;48(3–4):190–197
   PubMedGoogle Scholar
• . Smith MF Jr, Mitchell A, Li G, . Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-kappa B activation and chemokine expression by epithelial cells. J Biol Chem. 2003;278(35):325552–32560
   Web of Science ®Google Scholar
• . Draelos ZD, Ertel K, Berge C. Niacinamide-containing facial moisturizer improves skin barrier and benefits subjects with rosacea. Cutis. 2005;76(2):135–141
   PubMed Web of Science ®Google Scholar
• . Breneman D, Savin R, VandePol C, Vamvakias G, Levy S, Leyden J. Double-blind, randomized, vehicle-controlled clinical trial of once-daily benzoyl peroxide/clindamycin topical gel in the treatment of patients with moderate to severe rosacea. Int J Dermatol. 2004;43(5):381–387
   PubMed Web of Science ®Google Scholar
• . Goldman D. Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report. J Am Acad Dermatol. 2001;44(6):995–998
   PubMed Web of Science ®Google Scholar
• . Mostafa FF, El Harras MA, Gomaa SM, Al Mokadem S, Nassar AA, Abdel Gawad EH. Comparative study of some treatment modalities of rosacea. J Eur Acad Dermatol Venereol. 2009;23(1):22–28
   PubMed Web of Science ®Google Scholar
• . Karincaoglu Y, Bayram N, Aycan O, Esrefoglu M. The clinical importance of demodex folliculorum presenting with nonspecific facial signs and symptoms. J Dermatol. 2004;31(8):618–626
   PubMed Web of Science ®Google Scholar
• . Dahl MV, Jarratt M, Kaplan D, Tuley MR, Baker MD. Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea. J Am Acad Dermatol. 2001;45(5):723–730
   PubMed Web of Science ®Google Scholar
• . Shanler SD, Ondo AL. Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline. Arch Dermatol. 2007;143(11):1369–1371
   PubMedGoogle Scholar
• . Shanler S, Ondo A. Successful treatment of the erythema and flushing of rosacea using a topically applied selective 1-adrenergic receptor agonist, oxymetazoline (Abstract). J Am Acad Dermatol. 2008;58(2):AB9
   Web of Science ®Google Scholar
• . Schechter BA, Katz RS, Friedman LS. Efficacy of topical cyclosporine for the treatment of ocular rosacea. Adv Ther. 2009;26(6):651–659
   PubMed Web of Science ®Google Scholar